Gout Market Spotlight 2018: 10-Year Disease Prevalence Forecast, Licensing and Acquisition Deals, & Drug-Specific Revenue Forecasts - ResearchAndMarkets.com

DUBLIN--()--The "Market Spotlight: Gout" report has been added to ResearchAndMarkets.com's offering.

This Market Spotlight report covers the Gout market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

  • The approved drugs in the gout space focus on a wide variety of targets. They are commonly administered via the oral route, with the remainder being available in intravenous and subcutaneous formulations.
  • The majority of the industry-sponsored drugs in active clinical development for gout are in Phase II. Therapies in early and mid-stage development focus on targets such as uric acid, PPAR gamma, the IL-1 receptor, and the immune system/reactive oxygen species/free radicals. The majority of pipeline drugs are administered via the oral route, with the remainder being intramuscular, intravenous, and subcutaneous formulations.
  • There were seven licensing and asset acquisition activities involving gout drugs during 2013-17, three of which occurred in 2013. The exclusive licensing agreement in 2016 between Ironwood and AstraZeneca, worth $265m, for the US rights to Zurampic (lesinurad) and the fixed-dose combination of lesinurad and allopurinol, was the largest deal during the period.
  • Sales of Colcrys ranked highest among drugs in the gout space during 2012-16. However, during 2017-22, Ilaris is forecast to have the largest sales.
  • The clinical trials distribution across Phase I-IV indicates that the majority of trials for gout have been in early and mid-phases of development, with 68% of trials in Phase I-II, and 32% in Phase III-IV.
  • The US has a substantial lead in the number of gout clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • Clinical trial activity in the gout space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for gout, with 64 completed trials.
  • AstraZeneca has been the most active clinical trial sponsor for gout

Key Topics Covered:

1 KEY TAKEAWAYS

2 DISEASE BACKGROUND

  • Subtypes

3 TREATMENT

  • Non-steroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Colchicine
  • Combination therapy
  • Prevention of chronic gout

4 EPIDEMIOLOGY

5 MARKETED DRUGS

  • Approvals by country

6 PIPELINE DRUGS

7 KEY REGULATORY EVENTS

  • Duzallo Approval Opens Gout Opportunity For Ironwood
  • AZ's Gout Drug PASS-ed In Europe

8 LICENSING AND ASSET ACQUISITION DEALS

  • Recent deals

9 PARENT PATENTS

10 REVENUE OPPORTUNITY

11 CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase

12 BIBLIOGRAPHY

  • Prescription Information

Companies Mentioned

  • Ironwood
  • AstraZeneca

For more information about this report visit https://www.researchandmarkets.com/research/wrxpx3/gout_market?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorders Drugs, Musculoskeletal Disorders Drugs